

Roche launches Navify Mutation Profiler, Therapy Matcher

March 27, 2019—[Roche](#) announced the CE-IVD mark and launch of its Navify Mutation Profiler, clinical software that provides annotation, interpretation, and clinical reporting of next-generation sequencing tests. Roche launched also its Navify Therapy Matcher, an optional clinical decision support app that further aids clinicians in linking clinically actionable mutations to relevant therapy options.

Navify Mutation Profiler simplifies how labs report on their NGS tests, according to Roche.

Navify Mutation Profiler and Navify Therapy Matcher together offer a “clinical decision support solution that addresses a major workflow challenge for NGS labs, synthesizing large amounts of medical and scientific data into actionable insights,” Neil Gunn, head of Roche Sequencing Solutions, said in a statement.